AroCell AB (publ) announces today that the abstract entitled: "Quantification of cell loss in breast cancer during neoadjuvant treatment (NACT) assessed by serum thymidine kinase protein concentrations (sTK1)", by B Tribukait et al was published today by the ESMO Asia congress organizers (https://cslide.ctimeetingtech.com/asia2017/attendee/confcal/session/calendar?q=Tribukait).
The investigators quantified cell loss using the AroCell TK 210 ELISA kit to measure serum TK1 in serial samples from 145 breast cancer patients undergoing chemotherapy before surgery. Serum TK1 levels correlated to clinical/radiologically determined tumor response after cycles 2, 4 and 6, as well as pathologically determined response and disease-free survival. (To read the full abstract, please visit the ESMO Asia 2017 website.)
The investigators found that serum TK1 levels measured at the base-line and after completion of four cycles of treatment correlated significantly with clinical/radiological response during treatment and tumor-status at surgery. "This study shows that the reduction of tumor size and response to therapy can be assessed with our TK 210 ELISA" says Jan Stålemark, AroCell CEO. "Our product TK 210 ELISA was used in this study to investigate whether or not TK1 concentration can be a significant predictor of treatment response during chemotherapy of breast cancer. This is another study showing that serum TK1 measured with TK 210 ELISA is a promising biomarker for monitoring treatment response and possibly as a tool in clinical drug development. It gives a prompt signal on whether the new therapy works or not".
For additional information:
Jan Stålemark, CEO
AroCell AB (publ)
This information is information that AroCell is obliged to make public pursuant to the EU Market Abuse Regulation and the Securities Markets Act. The information was submitted for publication, through Jan Stålemark,at 09:30 CET on 08 November 2017.
AroCell AB (publ) is a Swedish company that develops standardized modern blood tests to support the prognosis and follow up of cancer patients. AroCell's new technology is based on patented methods to measure Thymidine Kinase 1 (TK1) protein levels in a blood sample. The TK 210 ELISA test provides valuable information mainly about the condition of cancer patients. This may help clinicians to optimize treatment strategies and estimate the risk of recurrence of the tumor disease during the monitoring of the disease. AroCell (AROC) is listed at Nasdaq First North and has about 2,500 shareholders. For more information, please seewww.arocell.com. Redeye AB is AroCell's Certified Adviser.
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: AroCell AB via Globenewswire